Lyvgen Biopharma Holdings Limited

Lyvgen Biopharma Co., Ltd.

Lyvgen Biopharma (suzhou) Co., Ltd.

Shanghai Svm Medical Technology Co., Ltd.

Yi Wu

Dong Wang

Jieyi Wang

Xiaobo Huang

Jian Sun

Jinjing Zhang

Song Zhang

Bin Zhu

Yundai Chen

Yun Long

Qian Zhai

Baoshi Han

Haoyu Yang

Haiquan Cao

Xiangde Zheng

Xinkang Wang

Sinan Sun

Longxiang Su

Hongli He

Yunping Lan

Zujun Tang

Disclosed herein are agnostic anti-CD40 antibodies and methods of using such for eliciting CD40 signaling, thereby enhancing immune responses, such as dendritic cell functions. The antibodies disclosed herein may be used to treat diseases, such as cancer and immune disorders.

Anti-CD40 antibodies and uses thereof

Disclosed herein are agonistic anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Anti-CD137 antibodies and uses thereof

Disclosed herein are humanized anti-CD137 antibodies and methods of using such for eliciting CD137 signaling, thereby enhancing immune responses such as T cell functions. The antibodies disclosed within may be used to treat diseases, such as cancer and immune disorders.

Humanized anti-CD137 antibodies and uses thereof

The disclosure provides CD40-binding molecules comprising engineered human IgG domains, for example, human IgG1, IgG2, and IgG4 variants having mutations in the hinge domain, which exhibit altered binding activity to one or more Fc&#x3b3; receptors. Also described herein are methods for selectively activating or inhibiting immune responses in a subject using the CD40-binding molecules.

Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof

Growing community of inventors

Shanghai, China

Yi Wu